Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer management

Elisabetta Bandiera, Chiara Romani, Claudia Specchia, Laura Zanotti, Claudio Galli, Giuseppina Ruggeri, Germana Tognon, Eliana Bignotti, Renata A. Tassi, Franco Odicino, Luigi Caimi, Enrico Sartori, Alessandro D. Santin, Sergio Pecorelli, Antonella Ravaggi

Research output: Contribution to journalArticle

93 Citations (Scopus)

Abstract

Background: The aim of this work was to analyze the diagnostic and prognostic value of serum human epididymis protein 4 (HE4) and Risk for Ovarian Malignancy Algorithm (ROMA) in epithelial ovarian cancer (EOC). Methods: Preoperative serum samples of 419 women (140 healthy controls, 131 ovarian benign cysts, 34 endometriosis, and 114 EOC) were tested for CA125 and HE4 using fully automated methods (Abbott ARCHITECT) and validated cutoff values. Results: For the discrimination of benign masses from EOC, in premenopausal women, the sensitivity and specificity were 92.3% and 59.4% for CA125, 84.6% and 94.2% for HE4, and 84.6% and 81.2% for ROMA, whereas in postmenopausal women, the sensitivity and specificity were 94.3% and 82.3% for CA125, 78.2% and 99.0% for HE4, and 93.1% and 84.4% for ROMA. In patients with EOC, elevated CA125, HE4, and ROMA levels were associated with advanced Federation of Gynaecologists and Obstetricians (FIGO) stage, suboptimally debulking, ascites, positive cytology, lymph node involvement, and advanced age (all P ≤ 0.05). Elevated HE4 and ROMA (both P ≤ 0.01), but not CA125 (P = 0.0579), were associated with undifferentiated tumors. In multivariable analysis, elevated HE4 and ROMA (all P≤0.05) were independent prognostic factors for shorter overall, disease-free, and progression-free survival. Conclusions and Impact: This study underlines the high specificity of HE4 in discriminating endometriosis and ovarian benign cysts from EOC and the high sensitivity of CA125 in detecting EOC. We showed HE4 and ROMA as independent prognostic factors. Multicenter studies are needed to draw firm conclusions about the applicability of HE4 and ROMA in clinical practice.

Original languageEnglish
Pages (from-to)2496-2506
Number of pages11
JournalCancer Epidemiology Biomarkers and Prevention
Volume20
Issue number12
DOIs
Publication statusPublished - Dec 2011

Fingerprint

Epididymis
Serum
Neoplasms
Proteins
Ovarian Cysts
Endometriosis
Ovarian epithelial cancer
Sensitivity and Specificity
Ascites
Multicenter Studies
Disease-Free Survival
Cell Biology
Disease Progression
Lymph Nodes

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer management. / Bandiera, Elisabetta; Romani, Chiara; Specchia, Claudia; Zanotti, Laura; Galli, Claudio; Ruggeri, Giuseppina; Tognon, Germana; Bignotti, Eliana; Tassi, Renata A.; Odicino, Franco; Caimi, Luigi; Sartori, Enrico; Santin, Alessandro D.; Pecorelli, Sergio; Ravaggi, Antonella.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 20, No. 12, 12.2011, p. 2496-2506.

Research output: Contribution to journalArticle

Bandiera, E, Romani, C, Specchia, C, Zanotti, L, Galli, C, Ruggeri, G, Tognon, G, Bignotti, E, Tassi, RA, Odicino, F, Caimi, L, Sartori, E, Santin, AD, Pecorelli, S & Ravaggi, A 2011, 'Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer management', Cancer Epidemiology Biomarkers and Prevention, vol. 20, no. 12, pp. 2496-2506. https://doi.org/10.1158/1055-9965.EPI-11-0635
Bandiera, Elisabetta ; Romani, Chiara ; Specchia, Claudia ; Zanotti, Laura ; Galli, Claudio ; Ruggeri, Giuseppina ; Tognon, Germana ; Bignotti, Eliana ; Tassi, Renata A. ; Odicino, Franco ; Caimi, Luigi ; Sartori, Enrico ; Santin, Alessandro D. ; Pecorelli, Sergio ; Ravaggi, Antonella. / Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer management. In: Cancer Epidemiology Biomarkers and Prevention. 2011 ; Vol. 20, No. 12. pp. 2496-2506.
@article{48c72614d70d4766b4655d8d9cf15bda,
title = "Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer management",
abstract = "Background: The aim of this work was to analyze the diagnostic and prognostic value of serum human epididymis protein 4 (HE4) and Risk for Ovarian Malignancy Algorithm (ROMA) in epithelial ovarian cancer (EOC). Methods: Preoperative serum samples of 419 women (140 healthy controls, 131 ovarian benign cysts, 34 endometriosis, and 114 EOC) were tested for CA125 and HE4 using fully automated methods (Abbott ARCHITECT) and validated cutoff values. Results: For the discrimination of benign masses from EOC, in premenopausal women, the sensitivity and specificity were 92.3{\%} and 59.4{\%} for CA125, 84.6{\%} and 94.2{\%} for HE4, and 84.6{\%} and 81.2{\%} for ROMA, whereas in postmenopausal women, the sensitivity and specificity were 94.3{\%} and 82.3{\%} for CA125, 78.2{\%} and 99.0{\%} for HE4, and 93.1{\%} and 84.4{\%} for ROMA. In patients with EOC, elevated CA125, HE4, and ROMA levels were associated with advanced Federation of Gynaecologists and Obstetricians (FIGO) stage, suboptimally debulking, ascites, positive cytology, lymph node involvement, and advanced age (all P ≤ 0.05). Elevated HE4 and ROMA (both P ≤ 0.01), but not CA125 (P = 0.0579), were associated with undifferentiated tumors. In multivariable analysis, elevated HE4 and ROMA (all P≤0.05) were independent prognostic factors for shorter overall, disease-free, and progression-free survival. Conclusions and Impact: This study underlines the high specificity of HE4 in discriminating endometriosis and ovarian benign cysts from EOC and the high sensitivity of CA125 in detecting EOC. We showed HE4 and ROMA as independent prognostic factors. Multicenter studies are needed to draw firm conclusions about the applicability of HE4 and ROMA in clinical practice.",
author = "Elisabetta Bandiera and Chiara Romani and Claudia Specchia and Laura Zanotti and Claudio Galli and Giuseppina Ruggeri and Germana Tognon and Eliana Bignotti and Tassi, {Renata A.} and Franco Odicino and Luigi Caimi and Enrico Sartori and Santin, {Alessandro D.} and Sergio Pecorelli and Antonella Ravaggi",
year = "2011",
month = "12",
doi = "10.1158/1055-9965.EPI-11-0635",
language = "English",
volume = "20",
pages = "2496--2506",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "12",

}

TY - JOUR

T1 - Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer management

AU - Bandiera, Elisabetta

AU - Romani, Chiara

AU - Specchia, Claudia

AU - Zanotti, Laura

AU - Galli, Claudio

AU - Ruggeri, Giuseppina

AU - Tognon, Germana

AU - Bignotti, Eliana

AU - Tassi, Renata A.

AU - Odicino, Franco

AU - Caimi, Luigi

AU - Sartori, Enrico

AU - Santin, Alessandro D.

AU - Pecorelli, Sergio

AU - Ravaggi, Antonella

PY - 2011/12

Y1 - 2011/12

N2 - Background: The aim of this work was to analyze the diagnostic and prognostic value of serum human epididymis protein 4 (HE4) and Risk for Ovarian Malignancy Algorithm (ROMA) in epithelial ovarian cancer (EOC). Methods: Preoperative serum samples of 419 women (140 healthy controls, 131 ovarian benign cysts, 34 endometriosis, and 114 EOC) were tested for CA125 and HE4 using fully automated methods (Abbott ARCHITECT) and validated cutoff values. Results: For the discrimination of benign masses from EOC, in premenopausal women, the sensitivity and specificity were 92.3% and 59.4% for CA125, 84.6% and 94.2% for HE4, and 84.6% and 81.2% for ROMA, whereas in postmenopausal women, the sensitivity and specificity were 94.3% and 82.3% for CA125, 78.2% and 99.0% for HE4, and 93.1% and 84.4% for ROMA. In patients with EOC, elevated CA125, HE4, and ROMA levels were associated with advanced Federation of Gynaecologists and Obstetricians (FIGO) stage, suboptimally debulking, ascites, positive cytology, lymph node involvement, and advanced age (all P ≤ 0.05). Elevated HE4 and ROMA (both P ≤ 0.01), but not CA125 (P = 0.0579), were associated with undifferentiated tumors. In multivariable analysis, elevated HE4 and ROMA (all P≤0.05) were independent prognostic factors for shorter overall, disease-free, and progression-free survival. Conclusions and Impact: This study underlines the high specificity of HE4 in discriminating endometriosis and ovarian benign cysts from EOC and the high sensitivity of CA125 in detecting EOC. We showed HE4 and ROMA as independent prognostic factors. Multicenter studies are needed to draw firm conclusions about the applicability of HE4 and ROMA in clinical practice.

AB - Background: The aim of this work was to analyze the diagnostic and prognostic value of serum human epididymis protein 4 (HE4) and Risk for Ovarian Malignancy Algorithm (ROMA) in epithelial ovarian cancer (EOC). Methods: Preoperative serum samples of 419 women (140 healthy controls, 131 ovarian benign cysts, 34 endometriosis, and 114 EOC) were tested for CA125 and HE4 using fully automated methods (Abbott ARCHITECT) and validated cutoff values. Results: For the discrimination of benign masses from EOC, in premenopausal women, the sensitivity and specificity were 92.3% and 59.4% for CA125, 84.6% and 94.2% for HE4, and 84.6% and 81.2% for ROMA, whereas in postmenopausal women, the sensitivity and specificity were 94.3% and 82.3% for CA125, 78.2% and 99.0% for HE4, and 93.1% and 84.4% for ROMA. In patients with EOC, elevated CA125, HE4, and ROMA levels were associated with advanced Federation of Gynaecologists and Obstetricians (FIGO) stage, suboptimally debulking, ascites, positive cytology, lymph node involvement, and advanced age (all P ≤ 0.05). Elevated HE4 and ROMA (both P ≤ 0.01), but not CA125 (P = 0.0579), were associated with undifferentiated tumors. In multivariable analysis, elevated HE4 and ROMA (all P≤0.05) were independent prognostic factors for shorter overall, disease-free, and progression-free survival. Conclusions and Impact: This study underlines the high specificity of HE4 in discriminating endometriosis and ovarian benign cysts from EOC and the high sensitivity of CA125 in detecting EOC. We showed HE4 and ROMA as independent prognostic factors. Multicenter studies are needed to draw firm conclusions about the applicability of HE4 and ROMA in clinical practice.

UR - http://www.scopus.com/inward/record.url?scp=83055178119&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=83055178119&partnerID=8YFLogxK

U2 - 10.1158/1055-9965.EPI-11-0635

DO - 10.1158/1055-9965.EPI-11-0635

M3 - Article

VL - 20

SP - 2496

EP - 2506

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 12

ER -